TheraVet Strengthens Its Intellectual Property With the Issuance of a Patent on VISCO-VET Technology in Europe, Israël & Singapore
January 30 2024 - 12:30AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
announces that the European Patent Office (EPO), and the
Singapore and Israel patent offices granted a patent covering
TheraVet VISCO-VET technology.
This patent, running until 2040, covers the manufacturing
process of a gel-forming composition as well as the composition
obtained by the said method. Patent applications with the same
subject matter are pending in the United States, China, Japan and
other territories. Two other patent applications on the VISCO-VET
technology are currently under examination.
VISCO-VET is a veterinary medicinal product currently under
clinical assessment in a prospective, multicentric, controlled,
double-blinded, randomized field study in client-owned dogs
suffering from osteoarthritis (OA). This study aims to evaluate the
potential of a unique intra-articular injection of VISCO-VET in
stifle or elbow – with a focus on elbow - to improve dog’s mobility
and reduce pain compared to a non-treated control group.
Enrico Bastianelli, Chief Executive Officer of
TheraVet, states: “We are pleased that our efforts to
strengthen our intellectual property have resulted in the issuance
of this key patent on VISCO-VET technology. We are continuing our
initiatives to protect our technologies in other main territories
and also through other patent families that are still pending.”
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129643955/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From May 2024 to Jun 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Jun 2023 to Jun 2024